A Food and Drug Administration members on Thursday, collectively supported wider use of Boston Scientific Corp.'s cardiac resynchronization therapy defibrillators in patients with mild-to-moderate heart breakdown.

Boston Scientific willingly suspended sales and recalled its defibrillators this week because of a documentation error that led to two mechanized changes not being accepted.

The FDA recommended doctors to avoid using devices until the time the errors are cleared.

A Wells Fargo Securities analyst, Larry Biegelsen, in a note to his investors stated that, FDA is expected to co-operate with Boston Scientific, at the earliest possible.

The surgically implanted devices lower the risk of death or heart failure in less complex cases by 34 percent, meeting the targets set out by researchers in a company-funded study, an FDA staff member assessed.

The wire that connects the device to the heart was also reported to have created troubles and complications.

The study, which was sponsored by Boston Scientific, included 1,800 patients with minor and major heart troubles or those that are considered to have Class I or Class II heart failure. The patients also had structural heart deformities. Around 700 patients received a defibrillator whereas nearly 1,100 received the CRT-D device.